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Abstract: Recent evidence suggests silicon dioxide micro- and nanoparticles induce cytotoxic 
effects on lung cells. Thus, there is an increasing concern regarding their potential health 
hazard. Nevertheless, the putative toxicity of nanoparticles in mammalian cells has not yet been 
systematically investigated. We previously noted that several metallic oxide nanoparticles exert 
differential cytotoxic effects on human neural and nonneural cells. Therefore, we hypothesized 
that silicon dioxide nanoparticles induce cytotoxicity in U87 cells by lowering their survival 
by decreasing cell survival signaling and disturbing mitochondrial function. To investigate this 
hypothesis, we determined the activities of the key mitochondrial enzymes, citrate synthase and 
malate dehydrogenase, in astrocytoma U87 cells treated with silicon dioxide nanoparticles. In 
addition, we studied the expression of the mitochondrial DNA-encoded proteins, cytochrome 
C oxidase II and nicotinamide adenine dinucleotide (NADPH) dehydrogenase subunit 6, and 
cell signaling pathway protein extracellular signal-regulated kinase (ERK) and phosphorylated 
ERK in treated U87 cells. The activated form of ERK controls cell growth, differentiation, 
and proliferation. In parallel, we determined survival of U87 cells after treating them with 
various concentrations of silicon dioxide nanoparticles. Our results indicated that treatment 
with silicon dioxide nanoparticles induced decreases in U87 cell survival in a dose-related 
manner. The activities of citrate synthase and malate dehydrogenase in treated U87 cells 
were increased, possibly due to an energetic compensation in surviving cells. However, the 
expression  of  mitochondrial  DNA-encoded  cytochrome  C  oxidase  subunit  II  and  NADH 
dehydrogenase subunit 6 and the cell signaling protein ERK and phosphorylated ERK were 
altered in the treated U87 cells, suggesting that silicon dioxide nanoparticles induced disruption 
of mitochondrial DNA-encoded protein expression, leading to decreased mitochondrial energy 
production  and  decreased  cell  survival/proliferation  signaling.  Thus,  our  results  strongly 
suggest that the cytotoxicity of silicon dioxide nanoparticles in human neural cells implicates 
altered mitochondrial function and cell survival/proliferation signaling.
Keywords: cytotoxicity, silicon dioxide nanoparticles, mitochondrial enzyme, extracellular 
signaling regulated kinase, cell signaling, neural cells
Introduction
According to the Environmental Protection Agency, exposure to nanomaterials can 
occur during the manufacturing or production process, and also has the potential to 
pollute the environment,1 in this case the occupational environment. A case in point 
is exposure to silicon dioxide nanoparticles because silicon dioxide, including a 
range of its particle sizes, is being used in cosmetics, food,2 and drug formulations.3 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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In general, silicon dioxide is viewed as a nontoxic substance 
and its industrial applications are numerous.2–4 Nevertheless, 
there have been reports, at least in the last two decades, that 
silicon dioxide particles are not as harmless as they were 
previously assumed to be.
When the size of silicon dioxide is above the micrometer 
scale (ie, .1 µm), it appears to be benign to human, insects, 
and microorganisms. However, diatomaceous earth, which 
contains more than 85% of amorphous silicon dioxide, is 
used as insecticide in dust form,4 but its toxicity to insects 
is not well defined. When the size of silicon dioxide is in 
the micrometer scale and below, several toxic effects have 
been observed in humans and animals. Most noticeable is 
the disease of silicosis in humans,5 resulting from prolonged 
exposure to crystalline silica dust, and similar symptoms have 
also been reported in rats.5 Thus far, silicon dioxide toxicity 
reports have been almost exclusively on particle sizes at the 
micrometer scale, and mostly concerning pulmonary injuries 
or lung inflammation.5,6 Few studies have been conducted on 
silicon dioxide at the nanometer scale,5,6 and even fewer stud-
ies so far reported have been conducted with human cells.
In macroscopic sizes, silicon dioxide is not known to be 
cytotoxic.2,3,5,6 However, a recent study demonstrated that 
exposure of amorphous spherical silicon dioxide nanoparticles 
of different sizes induced decreases in viability of human 
endothelial cells, an expression of their cytotoxicity which was 
apparently dependent on their particle size.7 Nevertheless, few, 
if any, studies have examined the putative cytotoxic effects of 
silicon dioxide nanoparticles on human neural cells.
There was an early study indicating that silica particles (in 
the micrometer and nanometer ranges) when introduced into 
the brains of rats and mice induced an inflammatory response 
in brain astrocytes and macrophages, and the degeneration 
of some adjacent axons and axon terminals, as elucidated 
by light and electron microscopy.8 Furthermore, silicon and 
aluminum were found to be co-localized in the central region 
of senile plaque cores in the cortex of patients with senile 
dementia of the Alzheimer type,9 and the accumulated silicon 
and aluminum appeared to be localized, at least in part, in 
lipofuscin granules in the brains of patients who died with 
Alzheimer’s disease.10 Consequently, these early studies8–10 
suggest that silicon dioxide nanoparticles may exert cytotoxic 
effects on neural cells.
We recently found that exposure to titanium dioxide and 
two other metallic oxide (namely, ZnO and MgO) nano-
particles induced differential cytotoxicity on human neural 
cells.11 Because of our recent findings11 and the increasing 
evidence that a variety of nanoparticles (including silicon 
dioxide-containing nanoparticles) can cross the blood–brain 
barrier,12,13 we initiated this study to investigate the putative 
cytotoxic effect(s) of silicon dioxide nanoparticles on human 
neural cells. In particular, we focused on investigation of 
the putative cytotoxic effects of these nanoparticles on 
mitochondrial function and survival cell signaling in human 
astrocytoma U87 cells that are astrocyte-like in view of 
the fact that they are good models of astrocytes normally 
found in the brain in vivo14,15 and that astrocytes in the brain 
are functionally coupled to endothelial cells and hence the 
functions of the blood–brain barrier.16,17
Because of the aforementioned considerations, we 
hypothesized that silicon dioxide nanoparticles induce 
cytotoxicity in U87 cells by disturbing mitochondrial function 
and by lowering cell survival via decreasing cell survival 
signaling. To investigate our hypothesis, we determined 
the effects of treatment with various concentrations of 
silicon dioxide nanoparticles on the activities of two key 
mitochondrial enzymes, ie, citrate synthase and malate 
dehydrogenase, and expression of the mitochondrial DNA-
encoded proteins, cytochrome oxidase subunit II and NADH 
dehydrogenase subunit 6, and the cell survival signaling path-
way protein ERK and phosphorylated ERK in U87 cells.
Materials and methods
Materials
Silicon dioxide nanoparticles (size 12 nm) were purchased 
from STREM Chemicals, Newburyport, MA. Dulbecco’s 
modified Eagle’s medium (DMEM) and other chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO). U87 cells 
were obtained from American Type Culture Collection 
(Manassas, VA).
cell culture
Human U87 astrocytoma cells were cultured using DMEM 
supplemented with 10% (v/v) fetal bovine serum and 
antimycotic solution. The cells were maintained in a 75 cm2 
flask containing 20 mL medium, incubated at 37°C in a CO2 
incubator. When the cells reached 70%–80% confluency, 
they were harvested either by scrapping or trypsinization 
and transferred to other flasks.
Preparation of stock suspension  
of silicon dioxide nanoparticles
The silicon dioxide nanoparticles stock suspension was 
first prepared by suspending 50 mg of silicon dioxide 
nanoparticles in a 100 mL conical flask containing sterile 
phosphate-buffered saline. The suspension was then placed International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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in a magnetic stirrer to allow the mixture to stir continuously 
at room temperature before further dilutions were made 
from the stock (which was being continuously stirred) to be 
used at specified concentrations and then mixed for use in 
treating cells.
MTT assay to assess cell viability
Cells were seeded (2000 cells/well) onto a 96-well plate and 
allowed to attach to the bottom of each well (inner diameter 
0.6 cm) for an hour. Silicon dioxide nanoparticles were 
then added at specified concentrations (0.1–100 µg/mL) to 
each well containing 0.2 mL with the cells attached at the 
bottom and mixed. The plates so prepared were incubated 
for 48 hours at 37°C. MTT dye was then added to each well 
and the plate incubated for another four hours at 37°C. The 
purple crystals formed in cells were dissolved using dimethyl 
sulfoxide and the absorbance of the resultant material in the 
wells was measured at 567 nm using the microplate reader 
as described previously.11
Determination of mitochondrial  
enzyme activity
The U87 cells were cultured in DMEM in 75 cm2 flasks. 
When the cells were 70%–80% confluent, silicon dioxide 
nanoparticle treatments were initiated. The mitochondrial 
function of the untreated and treated U87 cells was assessed 
by measuring activities of two tricarboxylic acid cycle 
enzymes, citrate synthase and malate dehydrogenase, in 
U87 cells treated with silicon dioxide nanoparticles at 0, 25, 
50, or 100 µg/mL by previously published methods.18 The 
untreated U87 cells served as the control. Citrate synthase 
and malate dehydrogenase activity in cell homogenates was 
measured at 412 nm and 340 nm, respectively, using an 
ultraviolet-VIS spectrophotometer.18
Western blot analysis
Expression of the mitochondrial DNA-encoded proteins, 
NADPH dehydrogenase subunit 6 and cytochrome C 
oxidase subunit II, and the cell signaling proteins ERK 
and phosphorylated ERK were determined by Western blot 
analysis. The U87 cells treated with or without (ie, control) 
silicon dioxide nanoparticles were collected and homogenized 
in a buffer containing 5 mM HEPES and 250 mM sucrose, 
along with protease inhibitors as described previously.15 Pro-
tein content of the homogenates was then determined using 
the bicinchoninic acid technique with a microplate reader.11 
Briefly, equal amounts of protein from the samples were loaded 
onto the lanes of the gels, and the proteins were separated 
by polyacrylamide gel electrophoresis and transferred to a 
polyvinylidene fluoride membrane.19 Monoclonal antibodies 
against the respective proteins were then used to probe the 
proteins of interest. The polyvinylidene fluoride membrane 
containing the target protein was then developed using the 
chemiluminescence technique on an X-ray film to assess the 
extent of expression of respective proteins.19
Assessment of cellular morphology
The morphology of the U87 cells, treated with silicon 
dioxide nanoparticles for 48 hours at 37°C using specified 
concentrations, were compared with that of the control or 
untreated U87 cells by using bright field light microscopy. 
The images were obtained using a Leica light microscope at 
400 × magnification (Leica DM IRB; Leica, Bannockburn, IL) 
equipped with a digital camera (Leica DFC 300FX; Leica).15
statistical analysis
Data analysis was performed employing one way ANOVA 
followed by Dunnett’s post hoc test using SPSS software 
(SPSS Inc., Chicago, IL). All data reported are mean ± SEM 
of three individual experiments. Statistical significance was 
set at P , 0.05.
Results
effect of nanoparticles on human U87 
astrocytoma cell survival
To determine the effect of silicon dioxide nanoparticles 
on cell survival, U87 cells were exposed to silicon dioxide 
nanoparticles for 48 hours at concentrations ranging from 0.1 
to 100 µg/mL. At lower treatment concentrations, from 0.1 
to 10 µg/mL, the nanoparticles did not affect viability of the 
U87 cells (Figure 1). However, at treatment concentrations of 
25 µg/mL and higher, silicon dioxide nanoparticles induced 
concentration-related decreases in survival of U87 cells. 
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Figure 1 effect of treatment with silicon dioxide nanoparticles on survival of human 
astrocytoma U87 cells. U87 cells were treated at specified concentrations of silicon 
dioxide nanoparticles for 48 hours. Values were the mean ± seM of at least three 
separate experiments; cTrL represented the untreated (ie, control) U87 cells; 
* P , 0.05 versus control cells.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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At the highest treatment level of 100 µg /mL, less than 30% 
of the cells survived (Figure 1).
effect on mitochondrial function  
in human U87 astrocytoma cells
Because cell survival critically depends on mitochondrial 
functions being maintained at a normal physiologic level, 
we determined the effect of silicon dioxide nanoparticles 
on mitochondrial function in U87 cells by monitoring the 
activities of citrate synthase and malate dehydrogenase.18 
Both enzymes are nuclear DNA-encoded; these enzyme 
proteins are synthesized in the endoplasmic reticulum and 
then imported into the mitochondrial matrix compartment.
At treatment concentrations of 25–100 µg/mL for 
48 hours, silicon dioxide nanoparticles induced dose-related 
increases in citrate synthase activities in U87 cells (Figure 2). 
On the other hand, although at the same concentrations the 
nanoparticles also induced significantly increased activity 
in malate dehydrogenase in U87 cells, the increases were 
not dose-related (Figure 3). Using the same nanoparticle 
concentrations for treatment of U87 cells, there was a dose-
related decrease in cell survival (Figure 1), and it is likely 
that the remaining surviving U87 cells were compensating by 
upregulation of citrate synthase and, to a less extent, malate 
dehydrogenase, so as to maintain their energy production via 
tricarboxylic acid cycle metabolism for survival.
effects of nanoparticles on mitochondrial 
DNA-encoded and cell signaling protein 
expression
Because silicon dioxide nanoparticles induced dose-related 
decreases in survival of U87 cells at concentrations of 
25–100 µg /mL over 48 hours (Figure 1), we investigated the 
possibility that these decreases in survival can be attributed 
to the nanoparticle-induced alterations in expression of 
mitochondrial DNA-encoded and cell signaling proteins 
(Figures 4–6).
At treatment concentrations of 25–100 µg/mL for 
48 hours, silicon dioxide nanoparticles induced dose-related 
decreases in the expression of cytochrome C oxidase subunit 
II and NADH dehydrogenase subunit 6 (two mitochondrial 
DNA-encoded peptides) in U87 cells (Figures 4 and 5). 
These results strongly suggested treatment with silicon 
dioxide nanoparticles altered the normal functioning of the 
mitochondrial genome in U87 cells. A likely consequence 
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Figure 2 Effect of treatment with silicon dioxide nanoparticles on specific activities 
of citrate synthase in human astrocytoma U87 cells. U87 cells were treated at 
specified concentrations of silicon dioxide nanoparticles for 48 hours. Then the 
activities  of  citrate  synthase  in  the  homogenates  of  treated  and  untreated  (ie, 
control, ctrl) U87 cells were determined as described in Materials and methods; 
the activities of citrate synthase were expressed per mg of homogenate protein as 
specific activities. The specific activities values were the mean ± seM of at least three 
separate experiments; ctrl represented the value in untreated U87 cell homogenate; 
* P , 0.05 versus that of control cells.
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Figure 3 Effect of treatment with silicon dioxide nanoparticles on specific activities 
of malate dehydrogenase in human astrocytoma U87 cells. U87 cells were treated 
at specified concentrations of silicon dioxide nanoparticles for 48 hours. Then the 
activities of malate dehydrogenase in the homogenates of treated and untreated (ie, 
control, ctrl) U87 cells were determined as described in Materials and methods; the 
activities of malate dehydrogenase were expressed per mg of homogenate protein as 
specific activities. The specific activity values were the mean ± seM of at least three 
separate experiments; ctrl represented the value in untreated U87 cell homogenate; 
* P , 0.05 versus that of control cells.
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Figure 4 effect of treatment with silicon dioxide nanoparticles on expression of 
cytochrome oxidase subunit II in human astrocytoma U87 cells. U87 cells were 
treated at specified concentrations of silicon dioxide nanoparticles for 48 hours. 
Then cell lysates of treated and untreated (ie, control) U87 cells were prepared 
as described in Materials and methods. The expression of cytochrome oxidase 
subunit  II,  encoded  by  mitochondrial  DNA,  was  determined  by  Western  blot 
analysis using β-actin as the loading control: Lane 1, lysate of untreated or control 
U87 cells; lane 2, lysate of U87 cells treated with silicon dioxide nanoparticles at 
25 µg/mL; lane 3, lysate of U87 cells treated with silicon dioxide nanoparticles at 
50 µg/mL; lane 4, lysate of U87 cells treated with silicon dioxide nanoparticles 
at 100 µg/mL. The blots were from a typical experiment. Two other experiments 
yielded essentially the same trend of results.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of this effect is impairment in the mitochondrial electron 
transport chain in U87 cells. Indeed, the nanoparticle-induced 
disruption of mitochondrial respiratory chain structure and 
function may be one cause of energy failure that ultimately 
led to the death of U87 cells.
Other than their effect of depressing the mitochondrial 
respiratory chain, thereby decreasing oxidative phos-
phorylation, treatment of U87 cells with silicon dioxide 
nanoparticles could also lower survival of U87 cells through 
altering cell signaling pathway(s) that regulate(s) cell 
survival and proliferation.20 We therefore   investigated this 
possibility by examining the effect of these nanoparticles 
on expression of ERK and phosphorylated ERK proteins. 
We observed that when U87 cells were treated with silicon 
dioxide nanoparticles 1–50 µg/mL for 48 hours, the protein 
expression of phosphorylated ERK showed a dose-related 
decrease, while that of ERK protein remained essentially 
unchanged (Figure 6), suggesting that a lowering of this cell 
survival/proliferation signaling mechanism could, at least 
in part, account for the dose-related decrease in U87 cell 
survival induced by these nanoparticles.
effect on morphology of U87 cells
To ascertain whether or not treatment of U87 cells with 
silicon dioxide nanoparticles led to any gross changes in 
their morphology, we examined the cells under bright field 
light microscopy (Figure 7). We observed that as we exposed 
U87 cells to increasing concentrations of silicon dioxide 
nanoparticles higher than 25 µg/mL, the cells became more 
and more enlarged and swollen, suggesting that they assumed 
a pathologic appearance (Figure 7).
Discussion
Few, if any, recent studies have addressed the cytotoxic 
effects of silicon dioxide nanoparticles in neural cells. 
As far as we are aware, ours is the first to report the 
cytotoxic effects of silicon dioxide nanoparticles on 
human astrocytoma U87 cells and some of the underlying 
subcellular mechanisms. Consistent with our hypothesis 
that silicon dioxide nanoparticles induce cytotoxicity in 
U87 cells by disturbing mitochondrial function and by 
lowering cell survival via decreasing cell survival signaling, 
we found that treatment with silicon dioxide nanoparticles 
induced concentration-related lowering of protein expression 
of the mitochondrial DNA-encoded cytochrome C oxidase 
subunit II and NADH dehydrogenase subunit 6, two key 
components of the mitochondrial respiratory chain, and 
phosphorylated ERK, a key cell survival/proliferation 
signaling molecule in U87 cells. It is noteworthy that we 
found those changes in protein expression at concentrations 
of silicon dioxide nanoparticles that correlated with those 
inducing concentration-related decreases in survival of 
U87 cells.
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Figure 5 effect of treatment with silicon dioxide nanoparticles on expression of 
nicotinamide  adenine  dinucleotide  (NADh)  dehydrogenase  subunit  6  in  human 
astrocytoma U87 cells. U87 cells were treated at specified concentrations of silicon 
dioxide  nanoparticles  for  48  hours.  Then  cell  lysates  of  treated  and  untreated 
(ie, control) U87 cells were prepared as described in Materials and methods. The 
expression of NADh dehydrogenase subunit 6, encoded by mitochondrial DNA, 
was determined by Western blot analysis using β-actin as the loading control: Lane 
1, lysate of untreated or control U87 cells; lane 2, lysate of U87 cells treated with 
silicon dioxide nanoparticles at 25 µg/mL; lane 3, lysate of U87 cells treated with silicon 
dioxide nanoparticles at 50 µg/mL; lane 4, lysate of U87 cells treated with silicon 
dioxide nanoparticles at 100 µg/mL. The blots were from a typical experiment. Two 
other experiments yielded essentially the same trend of results.
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Figure 6 effect of treatment with silicon dioxide nanoparticles on expression of 
extracellular  signal  regulated  kinase  (erK)  and  phosphorylated  erK  (p-erK)  in 
human astrocytoma U87 cells. U87 cells were treated at specified concentrations of 
silicon dioxide nanoparticles for 48 hours. Then cell lysates of treated and untreated 
(ie, control) U87 cells were prepared as described in Materials and methods. The 
expression  of  erK  and  phosphorylated  erK  was  determined  by  Western  blot 
analysis using β-actin as the loading control: Lane marked c, lysate of untreated 
or control U87 cells; lane marked 1, lysate of U87 cells treated with silicon dioxide 
nanoparticles at 1 µg/mL; lane marked 10, lysate of U87 cells treated with silicon 
dioxide nanoparticles at 10 µg/mL; lane marked 50, lysate of U87 cells treated with 
silicon dioxide nanoparticles at 50 µg/mL. The blots were from a typical experiment. 
Two other experiments yielded essentially the same trend of results.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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As emphasized earlier, the initial rationale for focusing 
our studies on U87 cells was that few studies have addressed 
the putative cytotoxic effects of silicon dioxide nanopar-
ticles on neural cells, especially those from the human 
brain. More importantly, not only do astrocytes have many 
physiologic roles (eg, metabolic trafficking, neurotrans-
mitter cycling, protecting neurons from pathophysiologic 
assaults),15,21,22 they also play pathophysiologic roles in 
disease states (eg, neuroinflammation in neurodegenera-
tive diseases such as Alzheimer’s disease and Parkinson’s 
disease).22 Furthermore, it is relevant to note that although 
U87 are neurotumor cells, they possess many of the “nor-
mal” physiologic characteristics of astrocytes detected in 
primary cultures of astrocytes and astrocytes in the brain 
in vivo.14,15 Thus, U87 cells constitute a good model system 
in vitro for brain astrocytes.14,15 Consequently, we have 
employed U87 cells as a model system to elucidate the 
putative cytotoxicity of nanoparticles on neural cells in a 
systematic manner.11
One neurotoxic effect of a neurotoxicant, such as 
manganese, is via a lowering of cell survival/prolifera-
tion signaling molecule expression, leading ultimately to 
death of neural cells.20 Consistent with this observation is 
our finding in this study that treatment of U87 cells with 
increasing concentrations of silicon dioxide nanoparticles 
induced a dose-related decrease in protein expression of 
phosphorylated ERK (Figure 6), one important cell survival/
proliferation signaling molecule.20 This effect correlated 
quite well with the dose-related decrease in survival of 
these cells (Figure 1) and alterations in their morphology 
(Figure 7) induced by the nanoparticles. Moreover, we also 
found that in U87 cells treated in the same nanoparticle dose 
SiO250 µg/mL SiO2100 µg/mL
Control SiO225 µg/mL
Figure 7 Effect of treatment with silicon dioxide nanoparticles on the morphology of human astrocytoma U87 cells. U87 cells were treated at specified concentrations 
of silicon dioxide nanoparticles for 48 hours. Then the morphology of treated and untreated (ie, control) U87 cells were assessed using bright field light microscopy at 
400 × magnification as described in Materials and methods. The photomicrographs shown were representative of those obtained in several studies.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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range, there was a concentration-related decrease in protein 
expression of mitochondrial DNA-encoded cytochrome C 
oxidase subunit II and NADH dehydrogenase subunit 6 
(Figures 4 and 5).
Our present findings that exposure of human astrocy-
toma U87 cells to silicon dioxide induced dose-related 
decreases in cell survival and alteration of their mitochondrial 
structure and function (Figures 1–6) are similar to those of 
Chen et al23 who demonstrated that exposure of human brain 
microvascular endothelial cells to aluminum oxide nanopar-
ticles induced decreased viability of those cells, alteration 
in their mitochondrial membrane potential, and a lowering 
of their tight junction protein expression. Consequently, 
in this context, our finding that silicon dioxide nanopar-
ticles induced a dose-related lowering of the expression of 
cytochrome C oxidase subunit II and NADH dehydrogenase 
subunit 6 is of pathophysiologic importance and interest in 
several respects. Because these two peptides are structural 
components of the mitochondrial respiratory chain com-
plexes IV and I, respectively, and have key functional roles 
in that respiratory chain,24 decreased expression of these 
peptides induced by the nanoparticles likely results in dys-
function in the mitochondrial respiratory chain and oxidative 
phosphorylation, leading ultimately to decreased adenosine 
triphosphate synthesis. Consequently, the decreased expres-
sion of the two mitochondrial DNA-encoded peptides could 
likely contribute to decreasing U87 cell survival induced 
by silicon dioxide nanoparticles through necrotic cell death 
as a result of energy failure.11 This conclusion is certainly 
consistent with our observation that the U87 cells assumed 
an increasingly swollen appearance, a hallmark of necrosis, 
as we increased their treatment levels of silicon dioxide 
nanoparticles (Figure 7). The decreased expression of cyto-
chrome C oxidase subunit II and NADH dehydrogenase 
subunit 6 peptides induced by the nanoparticles could reflect 
the effect of the nanoparticles on altering communication 
between the mitochondrial genome and the nuclear genome, 
decreasing mitochondrial peptide synthesis, disruption of 
protein targeting to mitochondria, and/or a combination 
of these mechanisms. The nanoparticle-induced decrease 
in protein expression of the two peptides could also result 
from the overall effect of the nanoparticles on survival/
proliferation signaling in U87 cells. Clearly, these are novel 
but mechanistically relevant possibilities that deserve further 
investigation.
Unlike the downregulation of the protein expression 
of mitochondrial DNA-encoded cytochrome C oxidase 
subunit II and NADH dehydrogenase subunit 6, and the 
survival/proliferation signaling molecule phosphorylated 
ERK, treatment of U87 cells with silicon dioxide nano-
particles induced concentration-related increases in the 
activity of citrate synthase and malate dehydrogenase, 
both of which are located in the mitochondrial matrix 
(Figures 2 and 3). Because the increases in citrate synthase 
and malate dehydrogenase activity were observed at 
nanoparticle concentrations that also induced dose-related 
decreases in U87 cell survival (Figure 1), one possible, and 
likely, explanation for the increased citrate synthase and 
malate dehydrogenase activity is that the surviving cells 
were showing compensatory/adaptive mechanisms involv-
ing upregulation of tricarboxylic acid cycle enzymes in the 
mitochondrial matrix of surviving or dying cells, or both, in 
the face of downregulation of mitochondrial DNA-encoded 
respiratory chain components, such as cytochrome C 
oxidase subunit II and NADH dehydrogenase subunit 6. 
Consequently, this upregulation of tricarboxylic acid cycle 
enzymes may offset (or compensate for) the effect on 
mitochondrial energetics through the downregulation of 
respiratory chain components induced by the nanoparticles. 
Only future studies can elucidate whether this mechanistic 
possibility is tenable because they are beyond the scope of 
the present study.
Because ours is the first study to report on the cytotoxic 
effects of silicon dioxide nanoparticles on human neural 
cells, only a few comparisons can be made with the effects 
of silicon dioxide nanoparticles on neural and peripheral 
cell types because the literature in this area of research is 
rather scant.11 For example, Napierska et al7 demonstrated 
exposure of human endothelial cells to amorphous spherical 
silicon dioxide nanoparticles induced decreases in their 
viability and this effect was apparently dependent on their 
particle size. Several groups had also shown that silicon 
dioxide nanoparticles decreased viability of some peripheral 
human and other mammalian cell types.5,25,26 Thus, recent 
reports,5,7,25,26 as well as the findings of this study, are in 
accord in emphasizing that silicon dioxide nanoparticles 
induces decreased viability of a variety of human and other 
mammalian cell types. Nevertheless, more systematic stud-
ies are required to elucidate fully the molecular mechanisms 
underlying the cytotoxicity of these nanoparticles.
As we discussed previously, one early study indicated 
that when silicon nanoparticles were introduced directly into 
the brains of rats and mice, they induced an inflammatory 
response in brain astrocytes.8 Furthermore, silicon was 
found in senile plaque cores and in lipofuscin granules in 
the cortex of patients who died of Alzheimer’s disease.9,10 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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In view of these earlier findings,8–10 because astrocytes 
play important roles in neuroinflammation,22 and U87 cells 
constitute a good cell model for astrocytes, the results 
of this study may have pathophysiologic implications in 
the inflammation in astrocytes in Alzheimer’s disease in 
particular and in neuroinflammation in general. Thus, the 
mechanistic connection between the inflammatory response 
in Alzheimer’s disease, neuroinflammation, and the cytotoxic 
effects of silicon dioxide nanoparticles in neural cells merits 
further investigation.
Conclusion
This study is the first to report on the cytotoxic effects 
of silicon dioxide nanoparticles on human astrocytoma 
U87 cells, and some of the underlying subcellular 
mechanisms. Consistent with our hypothesis, we found 
that treatment with silicon dioxide nanoparticles induced 
concentration-related lowering of protein expression in 
the mitochondrial DNA-encoded cytochrome C oxidase 
subunit II and NADH dehydrogenase subunit 6, two key 
components of the mitochondrial respiratory chain, and 
phosphorylated ERK, a key cell survival/proliferation sig-
naling molecule in U87 cells. We also noted those changes 
in protein expression induced by silicon dioxide nanopar-
ticles correlated with concentration-related decreases in 
survival of U87 cells induced by the nanoparticles. On the 
other hand, we observed upregulation of citrate synthase 
and malate dehydrogenase, two key tricarboxylic acid 
cycle enzymes. Those changes were likely compensatory/
adaptive mechanism of dying and/or surviving U87 cells. 
Thus, our findings may assume pathophysiologic impor-
tance in neuroinflammation and Alzheimer’s disease and 
in the environmental health impact of human exposure to 
these nanoparticles. This is obviously a worthwhile area 
for further study.
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